Research progress of B7-H3 in tumor growth,drug resistance formation and immunotherapy / 中国免疫学杂志

B7-H3(also known as CD276)is a newly discovered immune costimulatory molecule and a member of the B7 family of immune costimulatory molecules.Since the receptor of B7-H3 has not been identified yet,the specific mechanism of its immune function and intracellular signal transmission has not yet been clarified.B7-H3 is highly expressed in many malignant tumors,which indicates that not only B7-H3 can be used as a tumor marker for many malignant tumors to assist clinical diagnosis,which can be used as an effective target for tumor targeted therapy.This review mainly introduces the history of the development of the costimulatory mole-cule B7-H3 and its possible role in the development of various malignant tumors and the development of anti-tumor drug resistance,as well as the current mainstream therapeutic approaches targeting B7-H3.

Pharmacokinetics of antibody-drug conjugates and their research progress in the treatment of gastrointestinal malignancies / 药学学报

The morbidity and mortality of gastrointestinal malignancies are the highest in the world. For patients with poor response to conventional chemotherapy, new treatment methods are urgently needed. In recent years, under the background of precision medicine, antibody-drug conjugates (ADCs) with high tumor specificity and potent toxicity have become a hot research spot in the field of biomedicine. However, due to the complex structure and mechanism of ADCs, its pharmacokinetic research is facing great challenges which are the biggest resistance to the development of ADCs at present. In this case, it is of great significance to understand the pharmacokinetic properties of ADCs and make use of it to improve the efficacy of ADCs in the treatment of gastrointestinal malignancies. Based on the basic composition and mechanism of ADCs, this review summarizes the pharmacokinetic properties of ADCs, discusses its recent advances in the treatment of gastrointestinal malignancies, in order to provide more references for follow-up research on ADCs.

Advances in research on tumor targeted therapy of trastuzumab / 基础医学与临床

Trastuzumab is a humanized monoclonal antibody that targets at human epidermal growth factor receptor 2(Her2)proto-oncogenes,which can act on Her2 over-expression of tumor cells,inhibits tumor cells proliferation, differentiation,migration and other physiological activities,reduces the risk of tumor metastasis and extend the sur-vival time of patients.

Development of PEG-PLGA nanoparticles as drug carrier with tumor-targeted therapy / 国际外科学杂志

In recent years, tumor is a refractory disease occurring frequently which is the main cause of death. Surgery, radiotherapy and chemotherapy are the usual therapeutic tools. However,radiotherapy and chemotherapy have serious side-effects and surgery can not be used effectively when metastasis happened. Therefore, tumor-targeted therapy has developed as a better way to cure tumor. Development of research on the use of PEG-PLGA nanoparticles as drug carriers are reviewed in this article, furthermore, problems about that are analysed.